Hints and tips:
...Peter Bach, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering, said Gilead had often prioritised “revenue, market share and pricing power” and so it was not a surprise that...
...New York’s Memorial Sloan Kettering Cancer Center, one of the leading US cancer hospitals, last year launched an online tool called DrugAbacus to help healthcare providers assess the value of cancer drugs...
...Dr Peter Bach, director of Memorial Sloan Kettering’s health policy unit in New York, argues the practice of pushing ageing branded drugs over cheaper versions undermines industry claims that the ready availability...
...Peter Bach, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center in New York, says Mr Shkreli’s aggressive approach is the natural consequence of a US system that...
...Peter Bach, a doctor and director at the Memorial Sloan-Kettering Cancer Center in New York, reflects the views of many in his profession when he accuses it of “corrupting behaviour”....
...When doctors at Memorial Sloan Kettering Cancer Center in New York refused to use Sanofi’s Zaltrap colon cancer drug in 2012 because it cost twice as much as a rival product, the company backed down and...
...Along with his wife, Evelyn, he helped create the Evelyn H Lauder Breast Center at Memorial Sloan-Kettering Cancer Center in New York....
International Edition